CriticalSoluble guanylate cyclase (sGC) stimulator×Phosphodiesterase type 5 inhibitors (PDE5)
Updated · Methodology
Mechanism
Both activate cGMP pathway. Synergistic hypotension. FDA Adempas Section 4.3 strict contraindication.
Symptoms
Severe hypotension.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- EMA: Adempas (riociguat) SmPC, Section 4.3 (2024)– EMA EPAR Adempas
- AEMPS: Ficha técnica: Sildenafilo (nº registro 72231), sección 4.3 (2024)– AEMPS, CIMA, nº registro 72231, revisión 05/2024, sección 4.3